Printer Friendly

CRYOMEDICAL SCIENCES RECEIVES GRANT FORM NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO DEVELOP TEMPORARY BLOOD SUBSTITUTE

CRYOMEDICAL SCIENCES RECEIVES GRANT FORM NATIONAL HEART, LUNG AND
 BLOOD INSTITUTE TO DEVELOP TEMPORARY BLOOD SUBSTITUTE
 ROCKVILLE, Md., Oct. 8 /PRNewswire/ -- Cryomedical Sciences, Inc. (NASDAQ: CMSI) announced today that it has received a grant from the National Heart, Blood and Lung Institute for development of its proprietary hypothermic blood substitute solutions designed to protect the body under controlled hypothermia. The $50,000 Phase I Grant was awarded through the National Institutes of Health's Small Business Innovation Research (SBIR) program and is the maximum allowable under the program. Upon completion, CMS may apply for a phase II grant of $500,000.
 According to a company spokesman, "Although hypothermia is an established medical procedure for certain neurosurgical and cardiovascular procedures, its application and success has been limited due to a maximum time limit of approximately one hour of cardiac arrest before the onset of neurological damage. By increasing this limit to four or more hours we would achieve an important milestone in the development of this technology, which could result in 'bloodless' surgeries, allow new techniques for neuro, cardiac and micro surgeries, improve the viability of organs for transplantation and assist in the treatment of trauma victims."
 In laboratory animals undergoing this procedure, body temperature is lowered to approximately 10 degrees Celsius at which point complete metabolic arrest is achieved. The animal's blood is temporarily replaced with CMS' blood substitute. After approximately three to four hours of cardiac arrest, the animal is brought back to normal body temperature and reinfused with its own blood, whereupon it returns to a normal physiologic state. These results have previously been published in a number of medical journals and scientific meetings.
 Cryomedical Sciences, Inc. is a biomedical company engaged in the research, development, manufacturing and marketing of products in the field of low-temperature medicine.
 -0- 10/8/92
 /CONTACT: Edward Segal at STG Marketing Communications for Cryomedical Sciences, 202-333-7966, or J.J. Finkelstein of Cryomedical Sciences, 301-417-7070/
 (CMSI) CO: Cryomedical Sciences, Inc. ST: Maryland IN: MTC SU:


KD -- DC012 -- 7804 10/08/92 11:33 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 8, 1992
Words:340
Previous Article:'YEAR OF THE INDIANS' ACKNOWLEDGED BY MILLE LACS BAND OF OJIBWE AT BAND'S TWO CASINOS
Next Article:LUBY'S CAFETERIAS REPORTS RESULTS
Topics:


Related Articles
CRYOMEDICAL SCIENCES ADDS ROBERT SCHOELLHORN, FORMER CEO AND CHAIRMAN OF ABBOTT LABORATORIES, TO BOARD OF DIRECTORS
CRYOMEDICAL SCIENCES ANNOUNCES FISCAL YEAR 1992 BUSINESS AND FINANCIAL RESULTS
CRYOMEDICAL SCIENCES ANNOUNCES FISCAL YEAR 1993 BUSINESS AND FINANCIAL RESULTS; 35 CMS ACCUPROBE SYSTEMS SOLD; ORDER BACKLOG TOPS $10 MILLION
Oncogene Science Receives Funding to Discover and Develop Compounds to Treat Sickle Cell Disease and B-Thalassemia
Advanced Tissue Sciences Awarded $2 Million Grant for Tissue Engineered Vascular Grafts
New faces in DERT.
FDA approves new test for CHD biomarker: low LDL levels. (coronary heart disease, low density lipoprotein).
Northfield Laboratories Inc. Comments on Article and Editorial on Hemoglobin-Based Blood Substitutes to be Published in May 21 JAMA.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters